Active Clinical Trials at OOS

Tumor site:

Hematologic (MDS, CMML, AML)

Description:

**Enrollment Closed** A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting

Available at:

Our Salem Office

Tumor site:

Lung

Description:

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Lung

Description:

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Hematologic (MDS, CMML, AML)

Description:

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Prostate

Description:

***Enrollment closed*** A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Breast

Description:

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Lung

Description:

**Enrollment Closed** A Phase III, Randomized, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Lung

Description:

**Enrollment Closed** An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Solid Tumors

Description:

**Enrollment Closed** Compare the clinical relevant biomarkers identified by a novel BillionToOne quantitative ctDNA somatic mutation profiling assay with clinically available comparable assays in patients with advanced stage solid tumors.

Available at:

Our Salem Office

Tumor site:

Solid Tumors

Description:

Tumor methylation scores will be quantified at baseline across all tumor types to establish the clinical limit of detection of the assay. Associations between baseline tumor methylation score and PFS, OS, and disease control rate will be examined across therapeutic regimens and cancer types to test the hypothesis that the TMS is prognostic of outcome.

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

Tumor site:

Lung

Description:

**Enrollment Closed** A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Available at:

Our Salem Office

Tumor site:

Breast

Description:

**Enrollment Closed** An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

Available at:

Our Salem Office

Tumor site:

Lung

Description:

TEMPUS GEMINI (TP-CA-002) NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Colorectal Cancer

Description:

A Phase I/Ib global, multicenter, open-label umbrella study evaluating the safety and efficacy of targeted therapies in subpopulations of patients with metastatic colorectal cancer

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Lung (NSCLC)

Description:

Phase 3 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Breast; Lung

Description:

Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Breast

Description:

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »